论文部分内容阅读
丙型肝炎是一种主要经血液传播的疾病,丙型肝炎病毒感染可导致慢性化率为50%~85%,部分患者可发展为肝硬化甚至肝细胞癌,对患者的健康和生命危害极大,已成为严重的社会和公共卫生问题。近10多年来,聚乙二醇干扰素(PEG-IFN)已被用于慢性肝病和肝硬化治疗的临床研究,其持久的病毒应答、生物化学和组织学的应答显著高于传统的干扰素。本研究旨在探讨PEG-IFNα-2a治疗慢性丙肝的疗效及其影响因素,报告如下。
Hepatitis C is a major blood-borne disease. Hepatitis C virus infection can lead to a chronicity rate of 50% -85%. Some patients may develop cirrhosis or even hepatocellular carcinoma, which is extremely harmful to the health and lives of patients Big, has become a serious social and public health issue. For more than 10 years, pegylated interferon (PEG-IFN) has been used in clinical studies on the treatment of chronic liver disease and cirrhosis, and its long-lasting response to viral response, biochemistry and histology was significantly higher than that of conventional interferon . The purpose of this study is to investigate the efficacy of PEG-IFNα-2a in the treatment of chronic hepatitis C and its influencing factors, the report is as follows.